Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives Outperform Rating from William Blair

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “outperform” rating restated by equities researchers at William Blair in a research note issued on Friday,RTT News reports.

ALNY has been the subject of a number of other research reports. JPMorgan Chase & Co. boosted their price target on shares of Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 11th. Chardan Capital reissued a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday. Wells Fargo & Company boosted their price target on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an “equal weight” rating in a research note on Friday. StockNews.com cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $310.22.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $283.34 on Friday. The firm’s 50 day simple moving average is $257.16 and its 200 day simple moving average is $259.69. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The firm has a market capitalization of $36.68 billion, a PE ratio of -130.57 and a beta of 0.39. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, analysts expect that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Activity

In related news, CMO Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares of the company’s stock, valued at $3,416,865. This trade represents a 81.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Phillip A. Sharp sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,234 shares of company stock valued at $19,958,097. Corporate insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. California State Teachers Retirement System lifted its position in Alnylam Pharmaceuticals by 2.6% during the 4th quarter. California State Teachers Retirement System now owns 196,362 shares of the biopharmaceutical company’s stock valued at $46,206,000 after acquiring an additional 5,037 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in Alnylam Pharmaceuticals by 94.7% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 12,566 shares of the biopharmaceutical company’s stock valued at $2,957,000 after acquiring an additional 6,112 shares during the period. Lansforsakringar Fondforvaltning AB publ purchased a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $10,011,000. Bannerman Wealth Management Group LLC purchased a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $327,000. Finally, Siemens Fonds Invest GmbH lifted its position in Alnylam Pharmaceuticals by 137.7% during the 4th quarter. Siemens Fonds Invest GmbH now owns 3,245 shares of the biopharmaceutical company’s stock valued at $764,000 after acquiring an additional 1,880 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.